Immunogenicity of COVID-19 vaccines in lung cancer patients
Provencio Pulla, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Estival, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Franco, Fernando Fabio (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
López-Vivanco, Guillermo M. (Hospital Universitario de Cruces (Barakaldo, País Basc))
Saigí, Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Arasanz, Hugo (Hospital Universitario de Navarra)
Diz, Pilar (Complejo Asistencial Universitario de León)
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
García, Javier A. (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears))
Aguado, Carlos (Hospital Clínico San Carlos (Madrid))
Mosquera, Joaquín J. (Complejo Hospitalario Universitario de A Coruña)
Iruarrizaga, Eluska (Hospital Universitario de Cruces (Barakaldo, País Basc))
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau)
Bosch-Barrera, J. (Institut Català d'Oncologia)
Mielgo-Rubio, Xabier (Hospital Universitario Fundación Alcorcón)
Guirado Torres, María (Hospital General Universitario de Elche)
Juan-Vidal, Oscar José (Hospital Universitari i Politècnic La Fe (València))
Blasco Cordellat, Ana (Hospital General Universitario de Valencia)
Lucía Gozálvez, Clara (Hospital Universitari Sant Joan de Reus (Tarragona))
Del Barrio, Anabel (Hospital Universitario HM Sanchinarro (Madrid))
De Portugal, Teresa (Complejo Hospitalario de Zamora)
López-Martín, Ana (Hospital Universitario Severo Ochoa)
Serrano, Gloria (Hospital Universiario Infanta Leonor)
Campos, Begoña (Hospital Universitario Lucus Augusti (Lugo))
Rubio, Judit (Hospital Universitario de Móstoles (Madrid))
Catot, Sílvia (Althaia. Xarxa Assistencial Universitària Manresa)
Esteban, Beatriz (Hospital General Universitario de Segovia)
Martí-Ciriquian, Juan Luis (Hospital General Universitario de Alicante (Alacant, País Valencià))
Del Barco Morillo, Edel (Hospital Clínico Universitario (Salamanca))
Calvo, Virginia (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Universitat Autònoma de Barcelona

Date:	2023
Abstract:	Patients with lung cancer are at increased risk of SARS-CoV-2 infection and severe complications from COVID-19, but information on the efficacy of anti-SARS-CoV-2 vaccine in these patients is scarce. We aimed at evaluating the safety and immunogenicity of COVID-19 vaccines in this population. The prospective, nationwide SOLID substudy, enrolled adults with lung cancer who were fully vaccinated against COVID-19. Serum anti-SARS-CoV-2 IgG antibody levels were quantitatively assessed two weeks and six months after receipt of the last dose using a chemiluminescent microparticle immunoassay. Multivariate odds ratios for the association between demographic and clinical factors and seronegativity after vaccination were estimated. 1973 lung cancer patients were enrolled. Most patients had stage IV disease (66%) and were receiving active cancer treatment (82. 7%). No significant differences were found in the probability of being seronegative for anti-SARS-CoV-2 IgG antibodies after full vaccination between patients who were receiving active cancer treatment and those who were not (p = 0. 396). The administration of immunotherapy or oral targeted therapy and immunization with mRNA-1273 COVID-19 vaccine were factors independently associated with increased odds of being seropositive after vaccination. From all patients, 1405 received the second dose of vaccine and high levels of antibody titers were observed in 93. 6% of patients two weeks after second dose. At six months, multivariate logistic regression analysis showed that performance status ≥ 2 was independently associated with a higher probability of being seronegative after full vaccination with an OR 4. 15. On the other hand, received chemotherapy or oral target therapy and vaccination with mRNA-1273 were a factor independently associated with lower odds of being seronegative after full vaccination with an OR 0. 52, 0. 37 and 0. 34, respectively. Lung cancer patients can safely achieve a strong immune response against SARS-CoV-2 after full vaccination, regardless of the cancer treatment received. Trial registration: NCT04407143.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	COVID-19 ; Immune response ; Lung cancer ; Neutralizing antibodies ; SARS-CoV-2 ; Vaccine
Published in:	Lung cancer, Vol. 184 (october 2023) , p. 107323, ISSN 1872-8332

DOI: 10.1016/j.lungcan.2023.107323
PMID: 37639820

8 p, 548.7 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles